517 Effects of the oral janus kinase 1 (JAK1) inhibitor PF-04965842 on patient-reported outcomes (PROs) in adults with moderate to severe atopic dermatitis (AD)

Abstract

The International Dermatology Outcome Measures initiative defined a set of domains to be measured in all psoriasis clinical trials. Psoriatic arthritis (PsA) Symptoms is part of this set. This work seeks to define PsA screening in psoriasis clinical trials and to identify appropriate measures for PsA symptoms. The performance of 4 screening tools and the psychometric properties of 3 PsA symptoms measures (Patient Global (PG)-arthritis, Routine Assessment of Patient Index Data-3 (RAPID3) and Psoriatic Arthritis Impact of Disease (PsAID)) were presented to stakeholders in a pre-Delphi, face-to-face meeting. Participants voted on the role of PsA screening in psoriasis trials, and on the clinimetric properties of PG-arthritis, RAPID3 and PsAID. Of the 47 stakeholders who participated in the voting, 93% agreed that all psoriasis trial participants should be screened for PsA. Our tesults showed that 48% of the participants voted that PGarthritis matched the domain, 62% agreed that it was feasible, and 29% believed that it was sensitive to change. With regards to RAPID3, 61% felt that it was a good reflection of the domain, 65% claimed that it was feasible, and 54% voted that it was responsive. Finally, 58% of participants agreed PsAID was a good measure for PsA symptoms, 73% voted it was feasible, and 50% claimed it was responsive. This pre-Delphi study showed all psoriasis trial participants should be screened for PsA. RAPID3 and PsAID slightly outperformed PG-arthritis in measuring PsA symptoms. This will be followed by a Delphi-survey involving a larger stakeholder group.

Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata

“…Twenty studies [22–41] comprising 1851 patients with AD were published from 2015 to 2019 as full-text publications of abstracts presented at congresses ( n = 11) or scientific manuscripts ( n = 9) (Tables S4 and S8 of Supplementary Material). Seven studies (35%) previously registered an a priori protocol in a public registry.…”

“…Serious AE were observed in 9 patients (3.4%). No deaths were registered20 [41]RCT phase IIbAbrocitinib10/30/100/200 mg QD POSystemic12267 Pruritus NRS score PtGA POEM DLQI200 mg significantly improved ALL outcomes. 100 mg only pruritus NRS, DLQI, and POEMNA AEC absolute eosinophil count, SCORAD Severity Scoring of Atopic Dermatitis Index, EASI Eczema Area and Severity Index, NRS Numerical Rating Scale, EASI-75 ≥ 75% reduction of basal EASI value, POEM Patient Oriented Eczema Measure, PGA Physician’s Global Assessment, PtGA Patient’s Global Assessment, HRQoL Health-Related Quality of Life, IGA Investigator’s Global Assessment, VAS visual analogue scale, QD once a day, BID twice a day, PO per os (oral), DLQI Dermatology Life Quality Index, BSA body surface area, NA not acquired…”